Pharma

Listen to this article on the DDW Podcast: Chiedzo Mpofu, Vice President, Global Medical Affairs Head, Immunology, at AbbVie, talks to Lu Rahman about our understanding of auto-immune disease and how AbbVie is continuing to innovate in this field. “Immune mediated diseases are a diverse group of conditions that share common inflammatory pathways,” says Chiedzo Mpofu, […]

DDW Deputy Editor Reece Armstrong recently attended the Invest in Toulouse Virtual Round Table to find out how the city is establishing itself as a place of exciting research in the healthcare sectors.   Hosted by Jean-Claude Dardelet, the city’s Deputy Mayor, the roundtable examined how Toulouse is becoming an international destination for companies across various […]

GlaxoSmithKline (GSK) is to acquire biopharmaceutical company Sierra Oncology in a deal worth £1.5 billion, the company has announced.   Sierra Oncology  Sierra Oncology is a late-stage company focused on targeted therapies for the treatment of rare forms of cancer. The company’s lead asset, momelotinib, is being investigated as a treatment for myelofibrosis – a fatal […]

Digital biomarkers developer Winterlight Labs and memory clinic Alzheimer Center Amsterdam will work together on a project to decentralise assessments of patients’ cognition and function in the study of preclinical Alzheimer’s disease.   The project will see Alzheimer Center Amsterdam develop a remote measurement toolbox, integrating Winterlight’s digital speech assessments to help capture subtle changes in […]

Hettie Stroebel, Founder and CEO of Launch Excellence looks at how target product profiles can be used by life sciences companies as a strategy for more effective product development.    The global effort to develop and distribute a SARS-CoV-2 vaccine in months is a triumph for the pharmaceutical industry. It is also unprecedented. Never in the […]

James Tyrrell, Chair, Global Health, APCO Worldwide, assesses the pharmaceutical industry’s response to the Russian invasion of Ukraine and its ramifications on the sector.     With no quick end to Russia’s invasion of Ukraine, life sciences companies are increasingly being challenged to navigate this complex geopolitical crisis. Pharma and medtech companies’ products are not bound […]

The top 20 global innovative bio/pharma companies* reported a 24.9% growth in aggregate market capitalisation (MCAP)—from $2.8 trillion on 31 December 2020 to $3.4 trillion as of 31 December 2021, according to GlobalData.   The data and analytics company notes that a positive year-on-year MCAP growth was reported for 14 of the top players, with five […]

Biotechs involved in drug discovery have to navigate increasingly complex regulatory environments across borders. Experienced experts and non-executive advisors to Arriello, Eric Caugant, Principal Consultant at Pharmacovigilance Systems Consulting & Board advisor to Arriello, and Judi Sills, JM Sills Consulting & Board advisor to Arriello, highlight the main differences between US and EU requirements, and advise on […]

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks with Dr Orloff about his career and the future of […]

Pharming Group has announced the topline results from two randomised, open label, controlled, pilot clinical trials of patients hospitalised with Covid-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the seven-point WHO ordinal scale on Day Seven.  In the US study, which had included […]

News round-up by DDW’s Megan Thomas for 16-20 August  DDW’s Megan Thomas selects five news stories which spotlight the deals, collaborations and funding keeping the industry moving forward, enabling academics and drug developers to continue with life-saving research.   1. OGT training initiative with CytoCell University  OGT has expanded its activities with CytoCell University, an initiative that provides training to scientists […]

Monument Therapeutics, a stratified medicine company, today announced Monument Therapeutics the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Monument recently raised £2.625 million in seed funding and applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments.  The company has a pipeline of […]

BridgeBio Pharma has entered a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibitor, with OPDIVO (nivolumab) in patients with advanced solid tumours with KRAS mutations with the hope of providing an effective new treatment option for patients with difficult-to-treat cancers.  The collaboration will also include the initiation of a […]

Biotechs involved in drug discovery have to navigate increasingly complex regulatory environments across borders. Experienced experts and non-executive advisors to Arriello, Eric Caugant in Paris and Judi Sills in New Jersey highlight the main differences between US and EU requirements, and advise on best preparations. Small biotech companies are commanding an increasingly prominent role in […]

This is the latest episode of the free DDW podcast, “Stop, collaborate and listen: a model for successful pharma and vendor engagement”. It covers a narrated article written for DDW and read aloud by Megan Thomas. Digital transformations are having wide-ranging and profound impacts within life sciences, creating both opportunities and challenges. One of those […]

AlzeCure Pharma’s presentation and poster regarding the clinical candidate drug ACD856 for Alzheimer’s disease, presented at the Alzheimer’s Association International Conference (AAIC) 2021 on July 26-30 in Denver, USA, are now available on its website. The abstract, ACD856 – a novel positive allosteric modulator of Trk-signaling in clinical development for the treatment of Alzheimer’s disease, […]